Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Larry Todd Edwards Sells 2,052 Shares of Stock

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) insider Larry Todd Edwards sold 2,052 shares of the stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $25.50, for a total transaction of $52,326.00. Following the sale, the insider owned 148,865 shares in the company, valued at approximately $3,796,057.50. This trade represents a 1.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Larry Todd Edwards also recently made the following trade(s):

• On Thursday, November 6th, Larry Todd Edwards sold 29,131 shares of Arcutis Biotherapeutics stock. The stock was sold at an average price of $25.16, for a total value of $732,935.96.

Arcutis Biotherapeutics Stock Performance

Shares of ARQT opened at $26.08 on Thursday. The stock has a 50-day simple moving average of $28.23 and a 200-day simple moving average of $22.43. The company has a debt-to-equity ratio of 0.68, a quick ratio of 3.28 and a current ratio of 3.50. Arcutis Biotherapeutics, Inc. has a 1 year low of $11.13 and a 1 year high of $31.77. The stock has a market capitalization of $3.19 billion, a PE ratio of -72.44 and a beta of 1.70.

Hedge Funds Weigh In On Arcutis Biotherapeutics

Several institutional investors have recently added to or reduced their stakes in ARQT. Johnson Investment Counsel Inc. acquired a new stake in Arcutis Biotherapeutics during the 3rd quarter worth approximately $30,000. SBI Securities Co. Ltd. lifted its position in Arcutis Biotherapeutics by 325.4% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,089 shares of the company’s stock valued at $32,000 after purchasing an additional 833 shares during the period. PNC Financial Services Group Inc. grew its holdings in Arcutis Biotherapeutics by 10.2% during the second quarter. PNC Financial Services Group Inc. now owns 8,828 shares of the company’s stock worth $124,000 after acquiring an additional 820 shares during the period. Jones Financial Companies Lllp increased its holdings in Arcutis Biotherapeutics by 1,291.1% in the third quarter. Jones Financial Companies Lllp now owns 7,067 shares of the company’s stock valued at $124,000 after buying an additional 6,559 shares in the last quarter. Finally, Atlas Wealth LLC acquired a new stake in shares of Arcutis Biotherapeutics during the 2nd quarter valued at approximately $138,000.

Wall Street Analysts Forecast Growth

ARQT has been the topic of a number of analyst reports. Wall Street Zen cut Arcutis Biotherapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, January 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arcutis Biotherapeutics in a report on Monday, December 29th. The Goldman Sachs Group raised their price objective on shares of Arcutis Biotherapeutics from $19.00 to $29.00 and gave the stock a “neutral” rating in a report on Thursday, October 30th. Zacks Research downgraded shares of Arcutis Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 29th. Finally, HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Arcutis Biotherapeutics in a research report on Wednesday, October 29th. Six research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $29.20.

Key Headlines Impacting Arcutis Biotherapeutics

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Several analysts have maintained buy ratings and raised price targets (Needham, Mizuho, HC Wainwright among others); consensus remains a “Moderate Buy” with an average target near $29.20 — a positive catalyst that could limit downside from insider selling. MarketBeat ARQT analyst notes
• Neutral Sentiment: Short-interest data reported as effectively 0 shares as of Feb. 3 appears anomalous (NaN increase and 0.0 days-to-cover); this reading is unlikely to be meaningful for immediate price action. Institutional/hedge-fund position changes reported recently were small and incremental. MarketBeat short interest & institutional holdings
• Negative Sentiment: Multiple senior executives and a director disclosed sales totaling tens of thousands of shares (~46.7k shares across the filings, roughly $1.2M in proceeds across the named trades). Notable filings include Todd Watanabe (19,833 shares at ~$25.50), Masaru Matsuda (40,638 shares at ~$25.28), Director Howard Welgus (10,000 shares) and others (CFO Latha Vairavan, Patrick Burnett, Larry Todd Edwards). Coordinated/clustered insider selling can amplify near-term negative sentiment and pressure the stock. InsiderTrades alert on recent ARQT sales Todd Watanabe Form 4

Arcutis Biotherapeutics Company Profile

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.